Introduction
The hemp industry’s product landscape has expanded dramatically since the 2018 Farm Bill. What started as a CBD-centric market has evolved into a sprawling ecosystem of cannabinoids — delta-8 THC, delta-10 THC, THCO, CBN, CBG, and more — each with different chemical profiles, psychoactivity levels, and regulatory statuses.
The November 12, 2026 federal compliance deadline reshapes the status of virtually all intoxicating cannabinoids derived from hemp. For B2B buyers and brand formulators, understanding exactly what each compound is and where it stands post-November 12 is essential procurement knowledge. This glossary covers every major cannabinoid in the hemp market and answers the most important question for each: legal after November 12 or not?
CBD (Cannabidiol)
What it is: The most widely used non-intoxicating cannabinoid in hemp. CBD is a phytocannabinoid that occurs naturally in hemp plants at concentrations varying by cultivar and growing conditions.
How it’s produced: Extracted from hemp flower and biomass via CO2, ethanol, or hydrocarbon extraction. Broad-spectrum distillate retains multiple cannabinoids including CBD. CBD isolate is purified to 99%+ purity.
Psychoactivity: None at typical doses.
Post-November 12 status: LEGAL. CBD products that meet the 0.4mg total THC per container limit are fully compliant under the new federal standard. CBD isolate (which contains no THC) and properly formulated broad-spectrum distillate are the core of the compliant hemp ingredient market post-deadline.
CBG (Cannabigerol)
What it is: Often called the “mother cannabinoid,” CBG is a precursor compound from which CBD, THC, and other cannabinoids are biosynthesized. It occurs in relatively low concentrations in most hemp plants but can be cultivated in high-CBG specialty cultivars.
How it’s produced: Extracted from high-CBG hemp cultivars. CBG isolate has become increasingly available as the specialty cultivar market has developed.
Psychoactivity: None at typical doses.
Post-November 12 status: LEGAL. CBG does not contribute to the total THC calculation. Products formulated with CBG isolate or CBG-dominant broad-spectrum extract that stay within the 0.4mg total THC container limit are compliant.
CBN (Cannabinol)
What it is: A mildly psychoactive cannabinoid that forms from the degradation of THC when hemp is exposed to oxygen and light over time. CBN occurs naturally in aged hemp material and has been marketed primarily for sleep applications.
How it’s produced: Can be isolated from aged hemp extract or produced via chemical synthesis from CBD.
Psychoactivity: Mildly sedating at higher doses; much lower potency than THC.
Post-November 12 status: LEGAL with caveats. CBN itself is not included in the total THC calculation. However, CBN-containing products that also have elevated delta-9 THC or THCA may face compliance issues. The synthesis pathway from CBD also raises questions about whether synthetically derived CBN triggers different regulatory treatment.
Delta-8 THC
What it is: A psychoactive cannabinoid that is an isomer of delta-9 THC — same molecular formula, different double-bond position. Delta-8 occurs naturally in hemp at trace levels. Most commercial delta-8 is produced synthetically from CBD via isomerization.
How it’s produced: Predominantly via acid-catalyzed isomerization of CBD. The process often produces chemical byproducts that have raised safety concerns.
Psychoactivity: Moderate — roughly 50-70% of delta-9 THC potency according to most estimates. Produces euphoric effects.
Post-November 12 status: PROHIBITED. The new total THC standard applies to all THC isomers, not just delta-9. Delta-8 THC in a finished product counts toward the total THC calculation. A product with meaningful delta-8 content will almost certainly exceed the 0.4mg per container limit. Delta-8 products as currently formulated are effectively banned by the November 12 compliance framework.
Delta-10 THC
What it is: Another THC isomer, less potent than delta-8 and delta-9. Occurs in trace amounts naturally; commercial delta-10 is synthetically produced via isomerization of CBD.
Psychoactivity: Mild — lower potency than delta-8.
Post-November 12 status: PROHIBITED under the same logic as delta-8. Delta-10 is a THC isomer and is captured by the total THC calculation.
THCO (THC-O Acetate)
What it is: A synthetic cannabinoid produced by acetylating THC or delta-8 THC. THCO does not occur naturally in hemp. It is significantly more potent than delta-9 THC.
Psychoactivity: High — reportedly 2-3x more potent than delta-9 THC.
Post-November 12 status: PROHIBITED. The DEA issued a statement in February 2023 classifying delta-8 THCO and delta-9 THCO as Schedule I controlled substances because they are synthetic and do not occur naturally in the cannabis plant. THCO was never legally compliant hemp and remains prohibited.
THCA (Tetrahydrocannabinolic Acid)
What it is: The precursor to delta-9 THC. THCA is non-intoxicating in its raw form but converts to psychoactive delta-9 THC when heated (decarboxylation). THCA-rich hemp flower has been marketed as “compliant” hemp under old delta-9-only standards.
Post-November 12 status: CAPTURED in the total THC calculation. Total THC = delta-9 THC + (THCA × 0.877). THCA flower that was technically legal under the old standard is prohibited under the new total THC framework if it causes the container total to exceed 0.4mg.
What’s Still Legal Post-November 12: The Short List
- CBD (in compliant formulations) — Legal
- CBG — Legal
- CBN (in compliant formulations) — Legal with caveats
- Hemp seed oil and hemp protein (from seed, no cannabinoids) — Legal
🌿 LGH Perspective
At Low Gravity Hemp, our B2B ingredient catalog is built around the cannabinoids that survive November 12: CBD isolate, broad-spectrum distillate, CBG isolate, and nanoemulsified water-soluble hemp. We don’t supply delta-8, delta-10, or THCO — not because we can’t, but because our business model is built around the compliant market, not the gray market. For B2B buyers who need to know exactly what’s in their formulation and why it’s legal, that clarity is the point.
Final Thoughts
The hemp cannabinoid market has always been more complex than “CBD vs. THC.” The November 12 deadline simplifies that complexity in one direction: intoxicating cannabinoids — regardless of what they’re called — are out. Non-intoxicating cannabinoids in compliant formulations are in.
For B2B buyers, this glossary is a procurement filter: know what you’re buying, know where it stands after November 12, and source accordingly.
Contact Low Gravity Hemp to source compliant cannabinoid ingredients with full COA documentation for your post-November 12 formulations.
